The panel discussed various aspects related to the use of next-generation sequencing (NGS) and flow cytometry for minimal residual disease (MRD) detection in patients with various types of leukemia, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). They touched upon the challenges and benefits of using NGS for detecting MRD at greater detection depths. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The question arose as to whether…
Author: admin
In this lively debate, experts engage in a comprehensive analysis of Nelarabine’s efficacy in the treatment of ALL. The discussion covers its benefits and drawbacks, particularly focusing on its usage in EFS and DFS within the pivotal trial. Controversial points emerge regarding its impact on survival rates, with contrasting viewpoints on its effectiveness in pediatric and adult populations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The potential of combination…
In a dynamic and insightful debate, leading experts in the field of leukemia treatment delved into the intricacies of optimizing therapies for relapsed acute lymphoblastic leukemia (ALL). The discussion revolved around cost-effective strategies and clinical considerations for achieving enhanced outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The experts examined the potential of combining various treatments, including CAR T-cell therapy, to mitigate the escalating costs of managing relapsed ALL.…
We mourn the profound loss of Dr. Krystal Cascetta, a committed oncologist and breast cancer researcher. Our hearts extend to her family, friends, patients, and colleagues in these challenging times. In memory of her life and contributions, we highlight the severe mental health challenges faced by oncology professionals. Managing gravely ill patients, navigating intricate diseases, and daily confrontations with mortality exert a heavy emotional burden. Oncologists face higher rates of burnout, depression, and suicide compared to other physicians. It’s crucial that we foster a culture in oncology that forefronts mental health and well-being. Dr. Cascetta was not only a compassionate…
The panel discussion centered on the optimization of leukemia treatment, particularly focusing on the combination of venetoclax with various therapies. Preclinical data and pathophysiology were explored, highlighting the potential of inhibiting JAK2 mutations with venetoclax. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Concerns were raised about CNS relapse and CD19-negative relapses, emphasizing the need for continued IT chemotherapy. The balance between systemic chemotherapy reduction and comprehensive coverage with antigen-directed…
When discussing the myriad of cancers that affect humans, head and neck cancers, though slightly less talked about, remain a significant concern for medical professionals and patients alike. These cancers, which can originate in the oral cavity, throat, larynx, paranasal sinuses, and nasal cavity, are often diagnosed late due to their subtle initial symptoms. As a result, the need for effective treatments is palpable, especially for those cases where the disease has metastasized or recurred after initial treatment. Over the years, there’s been a growing interest in leveraging the body’s immune system to combat cancers, a treatment approach referred to…
The discussion centered on optimizing leukemia treatment strategies through the combination of immunotherapies and chemotherapy. The concern of CNS relapse and CD19-negative relapses was highlighted, emphasizing the importance of continued IT chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com While there is interest in reducing systemic chemotherapy, caution was advised due to potential resistance. The potential of combining antigen-directed therapies with chemotherapy for better coverage was discussed, along with…
This in-depth discussion among experts explores various facets of leukemia management. The conversation spans topics including challenges in clonotypable patients, the significance of MRD negativity in high-risk genetics, and the ongoing debate surrounding the necessity of transplantation for specific patient groups. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The experts also touch on practical considerations, such as the frequency of peripheral blood monitoring compared to bone marrow assessments.
Medical experts engaged in a discussion about advancing pediatric acute myeloid leukemia (AML) treatment strategies. Venetoclax, a promising drug, was a focal point, and its potential inclusion in pediatric protocols was explored. The challenge of adapting adult regimens to pediatric patients while considering drug forms suitable for children was discussed. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The importance of collaborative trials, merging efforts across pediatric and adult AML,…
Navigating the ever-evolving landscape of leukemia treatment has become an intricate endeavor, with recent clinical trials offering intriguing insights and sparking lively debates. These trials delve into the effectiveness of innovative therapies such as gilteritinib and midostaurin, potentially reshaping the foundation of standard care protocols. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Controversies emerge surrounding the significance of randomized studies in a rapidly changing environment, where salvage therapies like…
The conversation focuses on AML treatments, including arsenic and another frontline approach. Preventing relapses through non-toxic drugs like masitinib is explored. Financial obstacles and customized treatments are discussed. The importance of precise timing for treatments is highlighted. Myelosuppression and new dosing ideas are brought up. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Clinical trial design’s role in optimizing treatment is mentioned, with examples of challenges in drug approval. The need…
In this discussion, the focus is on optimizing Acute Myeloid Leukemia (AML) treatment. The idea of reducing drug doses upon achieving remission is challenged, questioning its efficacy against resistant disease. The notion of increasing drug doses to target resistance for improved outcomes is proposed. Perspectives diverge, with one side highlighting the need for conservative dosing to manage toxicities, while the other suggests early, aggressive intervention. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…
Leading experts engage in a comprehensive discussion on the intricate landscape of long-term remission and resistance patterns in transplanted acute myeloid leukemia (AML) patients, focusing on the potential role of Menin Inhibitor maintenance therapy. The dialogue delves into post-transplant outcomes and the emergence of resistance mutations, referencing previous presentations at the American Society of Hematology (ASH) meeting. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Central topics include the distinction…
Ryan Fitzpatrick, CEO, MD Education In opening the Focus Meeting 2023, Ryan Fitzpatrick, CEO, expresses gratitude to attendees and collaborators for their efforts. The importance of gathered speakers is emphasized, promising insightful discussions. Professional conduct and the value of fellows and junior faculty members are underscored. Logistical details, including breaks and a dinner, are outlined. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Online resources’ availability is noted, extending the…
The discussion revolves around complex topics related to acute myeloid leukemia (AML), including its groups, molecular markers, patient eligibility for clinical trials, and considerations of germline predisposition. Participants delve into the challenges of defining AML subtypes, the significance of molecular markers in diagnosis and treatment decisions, and the potential impact of germline factors on patient outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The conversation also touches on the…
In the ever-evolving landscape of medical science, melanoma and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) have remained two of the most formidable cancers to treat. Both of these cancers present unique challenges due to their aggressive nature and high recurrence rate. Yet, in the shadow of these challenges, targeted therapies have emerged as a beacon of hope. Targeted therapies are a relatively new addition to the oncological toolkit. Unlike traditional treatments that indiscriminately target both healthy and cancerous cells, targeted therapies focus precisely on the specific genes and proteins that are involved in the growth…
Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center. Joseph Corey, MD, Chair of Pathology and Microbiology at the University of Nebraska Medical Center, Omaha, presented a seminar on acute myeloid leukemia (AML) classification and its genetic underpinnings. The conference offered a platform for AML physicians and diagnostic specialists, like Corey, to exchange insights. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…
Harry Paul Erba, MD Professor of Medicine and Member of the Duke Cancer Institute Harry Erba, MD, a respected Duke University Medicine Professor, refines intensive chemotherapy for FLT3 mutated AML patients. He validates Midostaurin’s potential via the RATIFY trial and now focuses on potent second-gen FLT3 inhibitors. In the quantum first study, quizartinib enhances ITD mutated AML survival, particularly in younger patients (hazard ratio 0.68). Older patients also benefit, though less significantly (hazard ratio 0.9). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU…
Amir Fathi, MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital. Amir Fathi MD, an esteemed professional at Massachusetts General Hospital in Boston, Massachusetts, recently delivered a noteworthy presentation at a conference. His talk centered on induction strategies within the realm of patients lacking FLT3 mutations, showcasing the breadth of his expertise. The event proved to be a platform for various experts, including Amir’s colleagues, who shared compelling data. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration…
Alexander Edward Perl, MD, MS is a member of the leukemia program in the Abramson Cancer Center of the University of Pennsylvania and an Associate Professor of Medicine at the Perelman School of Medicine. Alexander E. Perl, MD, MS, an associate professor in the leukemia program at the Abrams Cancer Center, University of Pennsylvania, recently presented at a conference. He discussed identifying resistance mechanisms in FLT3 mutated AML patients and shared data-driven strategies for improved treatment. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/…
Courtney D. DiNardo, MD, MSCE Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Courtney DiNardo, MD, from MD Anderson Cancer Center, discussed IDH inhibitor therapy at a recent conference. She emphasized the benefits of combining IDH inhibitors with other treatments, showcasing a promising triplet therapy involving azacitidine, venetoclax, and IDH inhibitor. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com…
Eytan M. Stein, MD – Leukemia & Early Drug Development Specialist – David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center Eitan M. Stein, MD, Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City, delivered a presentation on the utilization of menin inhibitors in treating acute leukemia. The focus was on their application in patients with KMT2A rearrangements and NPM1 mutations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/…
Naval G. Daver, MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval G. Daver, MD, a faculty member at MD Anderson Cancer Center, co-chaired a successful symposium in Houston, Texas, featuring engaging presentations and active participation from junior faculty. Naval’s presentation focused on groundbreaking triplet therapies for acute myeloid leukemia patients unable to undergo intensive chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023…
Brian Andrew Jonas, MD, Ph.D. Associate Professor of Medicine (Clin X) – UC Davis Comprehensive Cancer Center Brian Jonas MD, Ph.D. from U.C. Davis sheds light on the latest advancements in AML treatment, focusing on the practical management of HMA Venetoclax. He delves into standard care approaches, recent progress, dosing adjustments, and toxicity mitigation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Sharing insights from prominent thought leaders at the conference,…
Marina Konopleva, M.D., Ph.D. Professor, Department of Oncology (Medical Oncology) and Department of Molecular Pharmacology Albert Einstein College of Medicine Jack and Pearl Resnick Campus Marina Konopleva, MD, PhD, is a distinguished name in the realm of medical research, serving as the Director of Leukemia at the renowned Einstein Medical Center in New York. With an esteemed cross-appointment at both Ambient’s and Casanthe, Licky Merplatte, Marina Konopleva stands as a prominent authority in the study of leukemia and its intricate treatment mechanisms. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…
Hi Nkem – I just wanted to reach out and introduce myself. I’m Allen Wilbanks here at OncologyTube. It seems our company aligns with Sanofi’s commitment to advancing oncology research and treatments. So I’m leaving my calendar link here: https://meetings.hubspot.com/allen12 Please book a date if you think it would be worth your time to chat. Thank you in advance. Cheers, Allen Wilbanks allen@oncologytube.com (951) 326-8827
Hi Maria, I’m Allen Wilbanks and I’m taking over all of Scott Nasiff’s accounts here at OncologyTube and I thought I’d reach out and introduce myself. I know you were working with Scott on the Takeda Oncology account last year and from this point forward I’ll be your contact here at OncologyTube. I would love to hear about your new projects so I’m including a link to my calendar here. https://meetings.hubspot.com/allen12 Cheers, Allen Wilbanks allen@oncologytube.com (951) 326-8827
Hi Frances, Hope you are well. You had reached out to OncologyTube on July 4th and I sent you some initial information about us such as we reach 35,000 HCP per month mainly oncologists and hematologists, in addition you asked us about our geographic reach. I just wanted to reach back out and say hi and ask if you have any more questions? If so please don’t hesitate to book an appointment with me here… https://meetings.hubspot.com/allen12 Cheers, Allen Wilbanks allen@oncologytube.com (951) 326-8827
Breast cancer is a topic that has garnered significant attention over the years, and for good reason. Affecting millions worldwide, it remains one of the most common forms of cancer among women. While early detection and advancements in treatment have improved prognosis for many, metastatic breast cancer (MBC) remains a significant challenge in the oncology world. By definition, metastatic breast cancer is when cancer has spread beyond the breast and axillary lymph nodes to other parts of the body. This form of cancer, often referred to as stage IV breast cancer, necessitates a deeper understanding and exploration of treatment options.…
Hi Dina, just wanted to say and let you know that we just registered for SABCS 2023 so we will be there if you need anything filmed. Also, we are ready whenever you are to launch the video pre-roll campaign or banners. Looking forward to working with you. Cheers, Allen
Farhad Ravandi-Kashani, M.D. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Farhad Ravandi, MD a distinguished professor of medicine at the University of Texas MD Anderson, delivered a captivating presentation on advancing disease assessment in AML patients at a recent conference. Professor Ravandi emphasized the significance of utilizing advanced tools and assays to detect residual leukemia, as emerging data strongly link any remaining leukemia cells to a heightened risk of relapse and poorer outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available -…
Marlise R. Luskin, MD, MSCE is a physician in Dana-Farber’s Adult Leukemia program. Meet Marlise Luskin, MD, MSCE, an esteemed Assistant Professor of Medicine and Senior Physician at Dana-Farber Cancer Institute in Boston, Massachusetts. With a focus on acute lymphoblastic leukemia, Marlise sheds light on the pivotal role of venetoclax in its treatment. Through insightful analysis of preclinical evidence, she explores the drug’s potential sensitivity against the disease, particularly when paired with diverse chemotherapy agents. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS…
Nitin Jain, MD. Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Nitin Jain, MD delved into the intricacies of T-cell Acute Lymphoblastic Leukemia (T-ALL). He highlighted the pressing medical void in this area and underscored the advent of innovative therapies. In particular, he focused on Chimeric Antigen Receptor T-cell (CAR-T) therapies, which hold immense promise for patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL…
Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD, MSCE discusses novel approaches within the context of CAR T-cell therapy to address the challenge of relapse, which is when cancer returns or resists treatment after an initial response. The two main mechanisms of relapse that she focuses on are loss of persistence (the CAR T cells’ ability to remain effective over time) and antigen modulation (changes in the cancer cells that make them less recognizable to CAR T cells). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US…
Shira N. Dinner, MD. Associate Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Sherra Diner, MD, an esteemed associate professor and leukemia physician at Northwestern University in Chicago, delves into a compelling discussion regarding the treatment of elderly adults with ALS. She emphasizes a departure from conventional chemotherapy approaches, advocating for the adoption of chemo-free and chemo-lite regimens. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Notably, the talk…
Hagop M. Kantarjian, MD. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX In the featured video, renowned expert Hagop Kantarjian, MD, a professor at MD Anderson Cancer Center, delves into groundbreaking developments in the treatment of adult acute lymphoblastic leukemia (ALL). With a focus on cutting-edge strategies, including third-generation TKIs like Ponatinib and Blinatumomab, as well as CD19/CD22-targeting antibodies, Hagop Kantarjian, MD underscores their promising potential to elevate cure rates while diminishing the demand for intensive chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online…
Tapan M. Kadia, MD. Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX Tapan Kadia, MD, a professor at MD Anderson Cancer Center, discusses acute myeloid leukemia (AML) maintenance therapy at the MD Education Conference. He highlights azacitidine as a standard treatment. After exploring various post-consolidation strategies, hypomethylating agents have emerged, extending remissions after stem cell transplantation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com…
Bijal Shah, MD, MS Hematology/Oncology H. Lee Moffic Cancer Center In the video, Bijal Shah, MD, MS discusses the significance of CAR T-cell therapy in treating B-cell Acute Lymphoblastic Leukemia (B-ALL) at the H. Lee Moffic Cancer Center. Shaw emphasizes the need to integrate CAR T-cell therapy early with novel agents, particularly in low disease burden scenarios, to improve outcomes for adults with B-ALL. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting…
Aaron Logan, MD – Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF) Meet Aaron Logan, MD Associate Professor of Clinical Medicine at the University of California San Francisco, who presented on the use of MRD (Minimal Residual Disease) to guide therapy in adults with acute lymphoblastic leukemia. In the evolving landscape of leukemia treatment, with blinatumomab moving to the forefront and the ECOG nineteen ten study showcasing benefits for patients achieving MRD negativity at the level of ten to the minus four, Aaron highlights the increasing importance of MRD assessment using high sensitivity NGS…
Anjali Advani, MD – Hematology and Medical Oncology – Cleveland Clinic Meet Anjali Ifani, MD the esteemed Director of the Inpatient Leukemia Unit at the renowned Cleveland Clinic. At a recent conference, she delivered an engaging talk on the integration of immunotherapy into front-line therapy for leukemia. Anjali also participated in a lively debate with Dr. Cassidy, focused on the incorporation of Blinatumumab versus Inetuzumab in frontline leukemia therapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register…
Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX This conference has been an outstanding success, bringing together a diverse and knowledgeable group of experts for engaging discussions and thought-provoking questions. The organization by the MD Education team was seamless and highly professional, and the choice of location was exceptional. Attendees expressed great satisfaction with the faculty’s presentations, which allowed ample time for in-depth discussions, debates, and sharing of viewpoints. The event provided a fantastic platform for networking with colleagues and peers while also benefiting from the expertise of specialists in…
Esophageal adenocarcinoma is a subtype of cancer that arises from the glandular cells in the esophagus, the muscular tube responsible for moving food from the mouth to the stomach. Known to be one of the most aggressive and potentially lethal forms of cancer, esophageal adenocarcinoma has become a major concern in oncology. According to the American Cancer Society, the incidence of this malignancy has been increasing, particularly in Western countries. With a rising prevalence, understanding and addressing esophageal adenocarcinoma become crucial. This involves recognizing the disease’s complexity, from its pathology to the effectiveness of current treatments. An urgent need for…
Dr. Kevin Harrington, Phd of the Royal Marsden Hospital, The Institute of Cancer Research, London, is the author of this OncologyTube.com video. August 5, 2023 Timestamps: 0:29 Why are ipilimumab and nivolumab used together? 0:39 What was the objective of the phase II CheckMate 714 trial? 1:40 How many patients were included in the trial, and what were the inclusion criteria? 3:23 What were the treatment regimens tested in the trial? 4:06 What were the primary endpoints of the trial? 5:33 Did the addition of ipilimumab to nivolumab improve the objective response rate in patients with recurrent or metastatic squamous…
Chronic Lymphocytic Leukemia (CLL), a type of cancer that begins in the bone marrow and invades the blood, is one of the most common adult leukemias. Affecting mainly older adults, it’s a condition that has seen a significant shift in treatment approaches and understanding over the years. CLL is a slow-growing leukemia where the bone marrow makes too many lymphocytes (a type of white blood cell). Unlike acute leukemias, CLL develops gradually and might not cause symptoms for a long time. It can be especially complex to manage in its previously untreated stage, as it may present unique challenges in…
Ann M. Gillenwater, MD – MD Anderson, Department of Head and Neck Surgery, Division of Surgery presents the First Safety and Efficacy Data of the Rakuten Medical Alluminox Treatment using ASP-1929 in Combination with anti-PD-1 for Recurrent and/or Metastatic Head and Neck Cancer at AHNS 2023. Questions: Can you please summarize the Phase 1b/2 study ASP-1929-181 that you presented this week at the American Head & Neck Cancer Society 2023 meeting? Can you please explain the Alluminox technology? Can you provide our viewers with information about any other Alluminox ASP-1929 data in head and neck cancer? Can you talk about…
Barbara Eichhorst, MD Professor of Medicine at UNIVERSITÄTSKLINIKUM KÖLN, is the author of this OncologyTube.com video. Timestamps: 0:09 Can you tell us about the CELL Trial and it´s design and any significant data. 3:04 How many patients were enrolled in the study and what were the characteristics of the patient population? 3:55 Can you touch on any adverse events that were seen in the study? 5:18 What are the common questions you’re asked by your colleagues about this data? 6:59 What are the key takeaways that you’d like to leave are oncologists viewers with and any final thoughts? 7:45 Is…
In this video, Dr. Samuel Klempner, MD summarizes the phase 3 STAR-221 clinical trial investigating a novel treatment for advanced upper gastrointestinal cancers.The STAR-221 study is comparing the combination of the immunotherapies domvanalimab, zimberelimab, and chemotherapy against standard chemotherapy plus nivolumab. It is enrolling over 700 patients with untreated, metastatic gastric, GE junction, or esophageal adenocarcinoma.The co-primary endpoints are progression-free and overall survival. Key secondary endpoints include response rate, duration of response, and safety. Dr. Klempner provides high-level overviews of the preliminary efficacy and safety data from the trial.He also discusses how PD-L1 expression is being analyzed to determine which…
Anju Replacement
Virginia Kaklamani, MD – UT Health San Antonio discusses Elacestrant (ORSERDU), an oral endocrine therapy, has been approved by the FDA for the treatment of advanced or metastatic breast cancer with ESR1-mutations. These mutations are found in up to 40% of tumors in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. A previous analysis showed that patients with ESR1-mut tumors who had prior CDK4/6 inhibitor (CDK4/6i) exposure for at least 12 months experienced a median progression-free survival (PFS) of 8.6 months with elacestrant compared to 1.9 months with standard of care (SOC).A new analysis of the…
Sarbajit Mukherjee, MD, MS, Assistant Professor, Roswell Park Comprehensive Cancer Center conducted a study to investigate the efficacy of a novel treatment approach for localized esophagogastric adenocarcinoma (EGAC). The standard treatment of pre-operative chemoradiation (CRT) followed by surgery leads to a pathologic complete response (pCR) rate of 20%. However, achieving pCR is associated with improved overall survival (OS). In this study, physicians aimed to increase the pCR rate by administering an innovative combination of FTD/TPI and oxaliplatin as induction chemotherapy (IC) prior to standard CRT.Between January 2020 and October 2022, patients eligible for potentially curative surgery with EGAC were enrolled…